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Tirofiban hydrochloride is a reversible antagonist of fibrinogen binding to the GPIIb/IIIa receptor, 
used for the treatment of acute coronary syndrome. A novel RP-HPLC method has been developed and 
validated for the determination of Tirofiban in serum of Wistar rats with and without deep acute venous 
thrombosis. The chromatographic separation was carried out using a reverse-phase HPLC column Puro-
spher® RP-18e (150 mm  4.6 mm i.d.; 5 μm) coupled with a guard column LiChrosorb® (4 mm  4 mm 
i.d.; 7 μm) and mobile phase consisting of the mixture of 1-octane sulfonic acid in water (pH 3.0, adjusted 
with orthophosphoric acid) and acetonitrile, with a ratio of 60 : 40 (v/v) and a flow rate of 1.0 ml/min, at a 
wavelength of 277 nm. The serum concentrations of Tirofiban in the group of rats with DVT were lower 
than those in the control group, and it could be explained with the binding of Tirofiban with the 
GPIIb/IIIa receptors.   
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РАЗВОЈ НА АЛТЕРНАТИВНA HPLC-МЕТОДA ЗА ОПРЕДЕЛУВАЊЕ ТИРОФИБАН  
ВО СЕРУМОТ НА СТАОРЕЦ 
 
Тирофибан хидрохлорид е реверзибилен антагонист на фибриногенот врзувајќи се за 
рецепторот GPIIb/IIIa, и се користи за третман на акутен коронарен синдром. Нова RP-HPLC-
метода е развиена и валидирана за определување на тирофибанот во серумот на Wistar стаорци со 
и без длабока акутна венска тромбоза. Хроматографското раздвојување се врши со помош на 
реверзно фазна HPLC-колона Purospher® RP-18E (150 mm  4.6 mm; 5 μm) во комбинација со 
претколона LiChrosorb® (4 mm  4 mm; 7 μm) и мобилна фаза која се состои од смеса на 1-октанска 
сулфонска киселина во вода (pH 3.0, се регулира со ортофосфорна киселина) и ацетонитрил во 
сооднос 60 : 40 (v/v) и проток од 1,0 ml/min, на бранова должина од 277 nm. Серумските 
концентрации на тирофибанот во групата стаорци со ДВТ беа пониски од оние во контролната 
група, што би можело да се објасни со врзување на тирофибанот за рецепторите GPIIb/IIIa. 
 
Клучни зборови: тирофибан; длабока акутна венска тромбоза (ДВТ); HPLC-определување;  
серум на стаорец 
 
 
1. INTRODUCTION 
 
Tirofiban hydrochloride, chemically described 
as N-(butylsulfonyl)-O-(4-[4piperidinyl]butyl)-L-ty-
rosine monohydrochloride monohydrate (Fig. 1), is 
a reversible non-peptide antagonist of fibrinogen 
binding to the major platelet surface glycoprotein 
(GP) IIb/IIIa receptor. In this way Tirofiban inhib-
its platelet aggregation. GP IIb/IIIa is involved in 
platelet aggregation using the tripeptide Arg-Gly-
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Asp (RGD) as a template [1, 2]. When adminis-
tered intravenously, Tirofiban inhibits ex vivo 
platelet aggregation in a dose- and concentration-
dependent manner. In combination with heparin 
and aspirin, it is used for the treatment of patients 
with unstable angina or non-Q-wave myocardial 
infarction, including patients who are to be man-
aged medically or those treated prior to angi-
ography/coronary intervention [3, 4]. Adjunctive 
therapy with GP IIb/IIIa-receptor inhibitors can 
reduce the incidence of cardiac ischemic events, 
including subsequent myocardial infarction (MI) 
and death, in patients with non-ST-segment-
elevation acute coronary syndromes [5]. It was 
shown that treatment with Tirofiban can reduce the 
rate of thrombotic cardiovascular events (com-
bined endpoint of death, myocardial infarction, or 
refractory ischemia/repeat cardiac procedure) in 
patients with non-ST elevation acute coronary 
syndrome (NSTE-ACS) [6, 7]. Ex vivo cultures of 
arterial rings confirmed that Tirofiban also activate 
growth-stimulatory signals in the endothelium. 
Thus, the benefits of tirofiban in those with acute 
coronary syndromes may be due to rapid endo-
thelization of damaged vessel, besides antiplatelet 
effects [1]. Platelet aggregation inhibition [8] is 
reversible following cessation of the infusion of 
Tirofiban. Tirofiban has a rapid onset and short 
duration of action when administered intravenous-
ly, with a half-life of approximately 2 hours. Also, 
90% inhibition is achieved by the end of a 30-
minute infusion [9]. Tirofiban is not strongly 
bound to plasma proteins. The unbound fraction in 
human plasma is around 35%. The distribution 
volume of Tirofiban in the steady state ranges from 
22 to 42 liters [10–12]. Experiments with the intra-
venous administration of 14C-labelled Tirofiban to 
healthy subjects show that it is cleared from the 
plasma largely by renal excretion, with about 65% 
of an administered dose appearing in urine and 
about 25% in feces [10, 11]. The drug was ap-
proved by the FDA in 1998, discovered by Merck, 
USA, and marketed under the brand name Ag-
grastat in the US by Medicure Pharma and the rest 
of the world by Irokocardio International SARL, 
Geneva [2, 12, 13].  
 
 
 
 
Fig. 1. Chemical structure of Tirofiban hydrochloride 
 
Very few methods have been reported for the 
determination of Tirofiban in biological samples [14, 
15]. According to data in the literature, reverse-phase 
chromatographic methods with acetonitrile and phos-
phate buffer solution [16] or 1-octane sulfonic acid 
solution at lower pH are used for the identification 
and quantification of Tirofiban [15, 17].  
In our previous work, we developed and val-
idated a RP-HPLC method using the mobile phase 
consisting of phosphate buffer (pH 5.2) and ace-
tonitrile (70:30, v/v) and a detection wavelength of 
274 nm [16]. Although we obtained good separa-
tion with the existing method, we aimed to achieve 
higher sensitivity and an increased range of meas-
urements. Therefore, our objective was to develop 
a sensitive, reproducible, rapid, and cost-effective 
RP-HPLC method with UV detection for the ther-
apeutic monitoring of the levels of Tirofiban in 
serum samples. 
 
 
2. EXPERMENTAL 
 
2.1. Chemicals and reagents 
 
Tirofiban hydrochloride as a Reference 
Standard was supplied by Merck (batch No. L-
000700462-006X027). Methanol and acetonitrile 
were HPLC grade and were provided by Sigma 
Aldrich. All other chemicals were analytical rea-
gent grade. Redistilled water was used to prepare 
solutions for mobile phase. 
 
2.2. Apparatus 
 
Chromatography was performed on a HPLC 
system 1200 series equipped with: binary pump 
SL, microvacuum degasser, standard autosampler 
ALS SL, column compartment TCC SL, diode 
array detector DAD SL from Agilent Technologies 
(Germany).  
 
2.3. Chromatographic conditions 
 
The separation was performed at room tem-
perature, using an isocratic method and reverse-
phase HPLC column Purospher® RP-18e (150 mm 
 4.6 mm i.d.; particle size 5 μm) coupled with a 
guard column LiChrosorb® (4 mm  4 mm i.d.; 
particle size 7 μm) from Merck KGaA (Darmstadt, 
Germany). The choice of solvent for the prepara-
tion of standard solutions and extraction of Tirofi-
ban from the blood was made considering the sol-
ubility of Tirofiban. Tirofiban is highly soluble in 
methanol. Methanol in the ratio of 3:1 in the blood 
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samples precipitated proteins so they do not inter-
fere with further analysis. 
The mobile phase, containing a mixture of 
1-octane sulfonic acid in water (pH 3.0, adjusted 
with orthophosphoric acid) and acetonitrile in the 
ratio 60 : 40 v/v and flow rate of 1.0 ml min–1, gave 
the best separation of peaks without interference 
from other components from the plasma including 
heparin, which we added as an anticoagulant.  
The injection volume of samples was 50 µl.   
Chromatographic data were analyzed using Chem-
Station software from Agilent Technologies (Ger-
many), following requirements for chromatograph-
ic analysis. Regression calculations were done with 
Microsoft Excel. 
 
2.4. Preparation of 1-octane sulfonic acid solution 
 
Two g of 1-octane sulfonic acid were 
weighed and transferred into a 1000-ml flask, and 
then water was added to the mark. The pH was 
adjusted to 3.0 with orthophosphoric acid 
 
2.5. Standard solutions and calibration curves 
 
The standard stock solution of Tirofiban was 
prepared by dissolving Tirofiban hydrochloride with 
methanol to achieve the concentration of Tirofiban 
in the range of 0.01–0.21 mg·ml–1. The calibration 
curve was constructed by plotting the ratio of the 
peak area of the drug against the drug concentration. 
All solvents and solutions for HPLC analysis were 
filtered using a membrane filter (0.45 μm pore size) 
and were vacuum degassed before use.  
 
2.6. Validation of the method 
 
The proposed method was validated accord-
ing to the guidelines set by the International Con-
ference of Harmonization for validation of analyti-
cal procedures [18, 19]. The precision and repro-
ducibility of the proposed method were evaluated 
by performing replicate analysis of the standard 
solutions and serum samples, to determine intra-
day and inter-day variability [within day (n = 5) 
and between days (n = 5)] for three different con-
centrations. Relative standard deviations were cal-
culated to obtain the precision of the method. The 
stock solution of Tirofiban was prepared by dis-
solving 25 mg of Tirofiban reference standard in 
methanol and diluted with methanol to 25 ml. 
Working standard solutions were prepared by ap-
propriate dilution with methanol to achieve final 
concentrations of Tirofiban (0.033 mg·ml–1, 0.1 
mg·ml–1 and 0.21 mg·ml–1). 
2.7. Recovery studies 
 
To establish the accuracy and reliability of 
the proposed method, recovery experiments were 
carried out by adding known amounts of the stand-
ard solution of Tirofiban to rat blood. Serum sam-
ples were used for this study and collected from 
normal rats before introducing the experimental 
model of deep venous thrombosis (DVT) in order 
to obtain a validated quantitative method suitable 
to monitor the concentration of Tirofiban and po-
tential degradation products in vivo after applica-
tion. Aliquots of 1 ml rat blood samples were 
spiked with Tirofiban standard solution to achieve 
final concentrations of Tirofiban: 0.033 mg·ml–1, 
0.1 mg·ml–1 and 0.21 mg·ml–1. The heparin was 
added as an anticoagulant. After heating in a water 
bath for 15 min., the tubes were centrifuged for 5 
min at 3500 rpm min–1. The supernatant was taken 
carefully, methanol was added for the precipitation 
of proteins in the ratio serum:methanol = 1:3 and 
then the tubes were centrifuged again for 5 min at 
3500 rpm min–1. The recoveries were calculated 
after five repeated experiments. The amount of 
Tirofiban in spiked rat serum samples was calcu-
lated from the linear regression equation.  
 
2.8. Limit of detection and limit of quantification 
 
The limit of detection (LOD) and limit of 
quantitation (LOQ) were calculated using follow-
ing formula: LOD = 3.3 SD/S and LOQ = 10 
SD/S, where SD is the standard deviation of the 
response (peak area) and S is the slope of the cali-
bration curve obtained.  
 
2.9. Experimental animal model 
 
In this study, male Wistar rats weighing 
220–250 g were used. The rats were randomly 
assigned into two groups: a control group (n = 18) 
and a group with experimentally induced deep 
venous thrombosis (n = 18). They were housed in 
cages and maintained in a controlled environment 
with free access to food and water. The experi-
mental animal model [3, 20] of venous thrombosis 
was induced by ligature of the femoral vein in rats. 
The hypercoagulability of blood was achieved by 
the intravenous administration of tissue thrombin 
[21, 22]. The rats were anaesthetized by intraperi-
toneal injection of water solution of Nesdonal 
(concentration 20 mg/kg body weight). The i.v. 
bolus dose of Tirofiban hydrochloride dissolved in 
sterile saline (0.6 mg/kg) was given to the rats 
through tail vein injection. Blood samples were 
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taken at 0, 5, 15, 30, 45, and 60 min post-dose in 
the presence of heparin and were collected in se-
rum tubes. They were centrifuged at 3500 rpm 
min–1 for 5 min, then serum was harvested and 
kept at –20 °C until analyzed. Then, methanol was 
added for protein precipitation in the serum : meth-
anol ratio (1 : 3). The tubes were then centrifuged 
again at 3500 rpm min–1 for 5 min and supernatant 
was injected into the HPLC column.  
 
3. RESULTS AND DISCUSSION 
 
Initial experiments were carried out using 
the mobile phase consisting of 1-octane sulfonic 
acid in water and acetonitrile in different propor-
tions and at different pH values. Mobile phase 
composition of 1-octane sulfuric acid in water (pH 
3.0, adjusted with orthophosphoric acid) and ace-
tonitrile (60:40, v/v) was found to be optimal for 
good peak resolution for Tirofiban and heparin 
with a retention time of 8.7 min and 11.4 min. for 
Tirofiban and heparin, respectively. The optimum 
wavelength for detection was 277 nm.  
System suitability tests as an integral part of 
each analytical HPLC methods was performed 
through evaluation of different parameters (reten-
tion time, tailing factor, retention factor, resolution, 
and selectivity) on freshly prepared standard stock 
solutions of Tirofiban. The retention times of Tiro-
fiban in methanol and rat serum samples were 8.7 
and 8.6 min, respectively. Tailing and retention 
factors for Tirofiban were obtained as 1.13 and 
1.21. Resolution factor for this system for Tirofi-
ban and heparin was 3.50. The variation in reten-
tion time of Tirofiban among five replicate injec-
tions of standard solution in methanol and rat se-
rum samples was very slight, giving the relative 
standard deviations (RSD %) of 0.54% and 0.73%, 
respectively.   
The calibration characteristics and validation 
parameters of the proposed method are shown in 
Table 1. Linearity of response was calculated as a 
ratio of peak areas of Tirofiban vs. concentration in 
methanol and spiked serum samples in the concen-
tration range of 0.033–0.21 mg·ml–1. Coefficient of 
correlation was greater than 0.99 for both media. 
The results of precision, accuracy (recov-
ery), and reproducibility (assay) of the method are 
shown in Table 2. They demonstrate a good preci-
sion (determined as the RSD %), accuracy, and 
reproducibility. 
 
 
                                T a b l e  1  
 
Characteristics of the linear regression analysis 
 
 Methanol Rat serum 
Linearity range (mg·ml–1) 0.033–0.21 0.033–0.21 
Slope 3561.1 3041.8 
Intercept –13.1235 –13.9671 
Determination coefficient (r2) 0.9991 0.9983 
SEa of the intercept 5.8008 6.7076 
SE of the slope 43.4632 50.2579 
Detection limit (mg·ml–1)      0.0053 0.0073 
Quantification limit (mg·ml–1) 0.0163 0.0221 
                     aSE – Standard error 
 
 
  T a b l e  2  
 
Precision and accuracy of the method 
 
Concentra-
tion added  
(mg·ml–1) 
 
Measured concentration (mg·ml–1)a 
 
 In methanol In rat serum 
 Intra-day 
Mean (mg·ml–1) 
± RSD (%) 
Inter-day 
Mean (mg·ml–1) 
± RSD (%) 
Intra-day Inter-day 
Mean (mg·ml–1) 
± RSD (%) 
Mean (mg·ml–1) 
± RSD (%) 
Recovery (%) 
 
0.033 0.0329 ± 0.96 0.0318 ± 1.17 0.0315 ± 1.54 95.45 0.0309 ± 0.87 
0.100 0.1023 ± 0.67 0.1025 ± 0.98 0.0985 ± 1.14 98.50 0.0974 ± 1.75 
0.211 0.2137 ± 1.13 0.2123 ± 1.45 0.2045 ± 1.39 96.92 0.2019 ± 0.93 
     a Mean value of five determinations 
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Figure 2a shows a typical chromatogram of 
the extract of the fresh blank serum sample. Figure 
2b shows the chromatogram of methanol used as a 
solvent. Figure 2c shows a chromatogram of Tiro-
fiban standard solution in methanol, while Figure 
2d shows a chromatogram of Tirofiban standard 
solution with heparin in methanol. Figure 2e shows 
the chromatogram obtained when the same method 
was applied to spiked rat serum samples. There are 
no extraneous peaks from endogenous substances 
in chromatograms obtained in serum samples.   
In our previous work [16], with a mobile phase 
containing of 0.1 M KH2PO4 (pH 5.2) and acetoni-
trile (70 : 30, v/v), the response was linear over the 
range of 0.03–0.18 mg·ml–1 and the limit of detection 
(LOD) for Tirofiban in rat serum was 13.8 μg ml–1.  
In the proposed method, the response was 
linear over the range of 0.033–0.21 mg·ml–1 and 
the LOD for Tirofiban in rat serum was twice as 
high (7.30 μg ml–1).  
Heparin was detected in both methods, with 
no reflecting importance, but with significant sepa-
ration from Tirofiban and without any effect on the 
calculation of results. 
All of the obtained results confirm that the 
proposed method can be applied in the direct deter-
mination of Tirofiban content in the serum. In our 
study, besides confirmation of the reciprocity of 
obtained results from the same injected dose in 
normal rats and rats with introduced experimental 
deep venous thrombosis, we attempted to present 
the impact of different concentration of Tirofiban 
during the same period. This was important to con-
firm the biodistribution and fast clearance of Tirofi-
ban in both groups and its potential availability to be 
used as a radioactive marker for the detection and 
definition of early deep venous thrombosis [23].  
 
 
 
  
 
 
  
 
 
 
Fig. 2. Chromatograms of blank serum (a), methanol used as solvent (b), Tirofiban in methanol (c),  
Tirofiban and heparin in methanol (d) and rat serum 5 min after a single i.v. bolus dose of 0.6 mg/kg Tirofiban (e). 
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The low concentration of Тirofiban will not 
affect the fibrinogen binding to the GPIIb/IIIa re-
ceptors, but will be enough to visualize the patho-
logical deviations in the circulation [24]. In Table 2, 
we present the results obtained by HPLC analysis of 
the spiked serum samples with Tirofiban. Serum 
concentrations of Tirofiban (mg/l) in male rats with 
and without DVT, after single i.v. bolus dose of 0.6 
mg/kg, measured after 5, 15, 30, 45 and 60 min, 
determined by HPLC, are shown in Figure 3. 
We calculated the percent of Tirofiban as a 
function of time after i.v. bolus injection. The re-
sults are presented in Table 3. 
 
 
 
 
Fig. 3. Concentrations of Tirofiban (mg/l) in the serum of 
male rats with and without DVT, after single i.v. bolus dose of 
0.6 mg/kg, measured after 5, 15, 30, 45 and 60 min. 
T a b l e  3  
 
The percent of Tirofiban in the serum of normal rat and rat with DVT after i.v. bolus injection 
 
Time after injection (min) 0 5 15 30 45 60 
Percent in the serum (%) after 0.6 mg/kg dose of Tirofiban 
Control group 100,00 55,23 29,85 23,34 19,10 17,00 
Experimental group 
(rats with introduced DVT) 
100,00 41,21 22,24 15,67 14,55 13,27 
 
 
From the percent presented in Table 3, we 
can see the difference between samples obtained 
from normal rats and samples from rats with intro-
duced fresh deep venous thrombosis. The results 
showed good agreement between two different 
groups of animals, but not between the different 
concentrations of injected Tirofiban. Here, 17% of 
injected doses found 60 minutes after injection in 
normal rats and the values of 13.27% in rats with 
DVT confirm the fast clearance of Tirofiban from 
the blood [14, 15]. Our results confirmed the vari-
ability between different concentrations of Tirofi-
ban and its metabolite in human samples, especial-
ly those obtained from patients with early DVT 
[23]. In our study, we did not consider determining 
the serum concentration in humans, so this will be 
the goal of our next investigation, after receiving the 
satisfactory result after the first labeling of Tirofiban 
with radioactive isotopes [23]. The good correlation 
in serum concentrations of different concentrations 
of Tirofiban obtained from experimental animals 
and from patients with acute DVT, will contribute to 
the idea that radiolabeled Tirofiban can be introduce 
as a potential radiopharmaceutical.  
 
4. CONCLUSION 
 
The proposed RP-HPLC method is a simple, 
accurate, precise and rapid for the determination of 
Tirofiban in the serum. The developed HPLC 
method was fully validated by evaluation of the 
validation parameters. Our results confirmed the 
aim of our study and showed the possibility of 
monitoring the concentration of Tirofiban in serum 
during the therapy, either given alone or in the 
presence of heparin.  
In our study we did not envision determining 
the serum concentration in humans, so this will be 
the goal of our next investigation, after receiving 
satisfactory results regarding the first labeling of 
Tirofiban with radioactive isotopes. Further, we 
could contribute to the idea that Tirofiban as a 
GPIIb/IIa antagonist is a potential imaging phar-
maceutical.  
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